title: Combined internal cardioverter-defibrillator implantation and myocardial revascularization for ischemic ventricular arrhythmias: optimal cost-effective strategy.
abstract: During the 7-year period from August 1986 to July 1993, 203 patients with malignant ventricular arrhythmias underwent 203 implantable cardioverter-defibrillator (ICD system) implantations at the University Hospitals of Cleveland. Sixty-four patients had significant coronary artery stenoses amenable to myocardial revascularization and thus, at the time of the operation for ICD placement, also underwent coronary artery bypass graft. A retrospective analysis of the course of these 64 patients was carried out to determine the effect of two different treatment strategies on the outcome and cost of therapy. Thirty-six patients (group 1) underwent concomitant implantation of the ICD leads, patches and generator at the time of myocardial revascularization; 28 patients (group 2) underwent a two-stage strategy of initial placement of the ICD leads and patches at the time of myocardial revascularization followed by postoperative electrophysiologic testing to determine the persistent need for generator implantation. Of this latter group, 16 patients still had inducible sustained ventricular tachycardia during postoperative electrophysiologic testing and underwent generator implantation; 12 patients did not receive an ICD generator. The overall 30-day mortality rate was 4.7%. Two patients died in group 1 for a mortality rate of 5.5% and one died in group 2 for a mortality rate of 3.6%. The mean(s.d.) length of stay was 22.8(9.6) days at a mean(s.d.) cost of $93,000(33,000) for group 1 and 24.5(9.6) days at a mean cost of $82,900(30,000) for group 2 (P = n.s.). The mean(s.d.) postoperative length of stay was 13.7(7.8) days for group 1 and 15.4(6.5) days for group 2 (P = n.s.). Other complications occurred in 23% of surviving patients in group 1 and 29% of surviving patients in group 2 (P = n.s.). Mean follow-up was 33 months for group 1 and 23 months for group 2. At the end of 2 years, 78% of patients in group 1 and 86% in group 2 were alive (P = n.s.).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Divisions of Cardiothoracic Surgery, Case Western Reserve University School of Medicine, Ohio, USA.
authors.forename: J H
authors.initials: JH
authors.lastname: Lee
authors.forename: D L
authors.initials: DL
authors.lastname: Folsom
authors.forename: L A
authors.initials: LA
authors.lastname: Biblo
authors.forename: M D
authors.initials: MD
authors.lastname: Carlson
authors.forename: N J
authors.initials: NJ
authors.lastname: Johnson
authors.forename: A L
authors.initials: AL
authors.lastname: Waldo
authors.forename: A S
authors.initials: AS
authors.lastname: Geha
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D001026:Coronary Artery Bypass / Q000191:economics*; D003327:Coronary Disease / Q000191:economics / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D003362:Cost-Benefit Analysis; D017147:Defibrillators, Implantable / Q000191:economics*; D005260:Female; D006801:Humans; D007902:Length of Stay / Q000191:economics; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000191:economics / Q000401:mortality / Q000503:physiopathology; D012086:Reoperation / Q000191:economics; D012189:Retrospective Studies; D015996:Survival Rate; D017180:Tachycardia, Ventricular / Q000191:economics / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D016896:Treatment Outcome